These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

352 related articles for article (PubMed ID: 26099227)

  • 1. Early side effects and first results of radioligand therapy with (177)Lu-DKFZ-617 PSMA of castrate-resistant metastatic prostate cancer: a two-centre study.
    Ahmadzadehfar H; Rahbar K; Kürpig S; Bögemann M; Claesener M; Eppard E; Gärtner F; Rogenhofer S; Schäfers M; Essler M
    EJNMMI Res; 2015 Dec; 5(1):114. PubMed ID: 26099227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic response and side effects of repeated radioligand therapy with 177Lu-PSMA-DKFZ-617 of castrate-resistant metastatic prostate cancer.
    Ahmadzadehfar H; Eppard E; Kürpig S; Fimmers R; Yordanova A; Schlenkhoff CD; Gärtner F; Rogenhofer S; Essler M
    Oncotarget; 2016 Mar; 7(11):12477-88. PubMed ID: 26871285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcome and safety of rechallenge [
    Yordanova A; Linden P; Hauser S; Meisenheimer M; Kürpig S; Feldmann G; Gaertner FC; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2019 May; 46(5):1073-1080. PubMed ID: 30474706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal outcomes of radioligand therapy: experience of
    Gallyamov M; Meyrick D; Barley J; Lenzo N
    Clin Kidney J; 2020 Dec; 13(6):1049-1055. PubMed ID: 33391748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective Study.
    Banda A; Privé BM; Allach Y; Uijen MJM; Peters SMB; Loeff CC; Gotthardt M; Muselaers CHJ; Witjes JA; van Oort IM; Sedelaar JPM; Westdorp H; Mehra N; Khreish F; Ezziddin S; Sabet A; Kreissl MC; Winkens T; Seifert P; Janssen MJR; van Gemert WAM; Nagarajah J
    Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612293
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and Haematologic Toxicity of Palliative Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with Lutetium-177-Labeled Prostate-Specific Membrane Antigen in Heavily Pre-Treated Patients.
    Kesavan M; Meyrick D; Gallyamov M; Turner JH; Yeo S; Cardaci G; Lenzo NP
    Diagnostics (Basel); 2021 Mar; 11(3):. PubMed ID: 33799431
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Renal Safety of [
    Rosar F; Kochems N; Bartholomä M; Maus S; Stemler T; Linxweiler J; Khreish F; Ezziddin S
    Cancers (Basel); 2021 Jun; 13(12):. PubMed ID: 34205686
    [No Abstract]   [Full Text] [Related]  

  • 8. Dosimetry for (177)Lu-DKFZ-PSMA-617: a new radiopharmaceutical for the treatment of metastatic prostate cancer.
    Delker A; Fendler WP; Kratochwil C; Brunegraf A; Gosewisch A; Gildehaus FJ; Tritschler S; Stief CG; Kopka K; Haberkorn U; Bartenstein P; Böning G
    Eur J Nucl Med Mol Imaging; 2016 Jan; 43(1):42-51. PubMed ID: 26318602
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In Comparison to PSA, Interim Ga-68-PSMA PET/CT Response Evaluation Based on Modified RECIST 1.1 After 2
    Prasad V; Huang K; Prasad S; Makowski MR; Czech N; Brenner W
    Front Oncol; 2021; 11():578093. PubMed ID: 33816225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and Safety of [
    Rosar F; Krause J; Bartholomä M; Maus S; Stemler T; Hierlmeier I; Linxweiler J; Ezziddin S; Khreish F
    Pharmaceutics; 2021 May; 13(5):. PubMed ID: 34069003
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Bu T; Zhang L; Yu F; Yao X; Wu W; Zhang P; Shi L; Zang S; Meng Q; Ni Y; Shao G; Qiu X; Ai S; Jia R; Guo H; Wang F
    Front Oncol; 2022; 12():835956. PubMed ID: 35402274
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Yadav MP; Ballal S; Tripathi M; Damle NA; Sahoo RK; Seth A; Bal C
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):81-91. PubMed ID: 27506431
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of Response to Radioligand Therapy of Metastatic Castrate-Resistant Prostate Cancer with 177Lu-PSMA-617.
    Ferdinandus J; Eppard E; Gaertner FC; Kürpig S; Fimmers R; Yordanova A; Hauser S; Feldmann G; Essler M; Ahmadzadehfar H
    J Nucl Med; 2017 Feb; 58(2):312-319. PubMed ID: 27587707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of
    Mader N; Groener D; Tselis N; Banek S; Nagarajah J; Grünwald F; Sabet A
    Cancers (Basel); 2021 Aug; 13(16):. PubMed ID: 34439347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Delayed response after repeated
    Rahbar K; Bögeman M; Yordanova A; Eveslage M; Schäfers M; Essler M; Ahmadzadehfar H
    Eur J Nucl Med Mol Imaging; 2018 Feb; 45(2):243-246. PubMed ID: 29134280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The
    Scarpa L; Buxbaum S; Kendler D; Fink K; Bektic J; Gruber L; Decristoforo C; Uprimny C; Lukas P; Horninger W; Virgolini I
    Eur J Nucl Med Mol Imaging; 2017 May; 44(5):788-800. PubMed ID: 28083690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of Overall and Disease-Free Survival in Metastatic Castration-Resistant Prostate Cancer Patients Receiving
    Sathekge M; Bruchertseifer F; Vorster M; Lawal IO; Knoesen O; Mahapane J; Davis C; Reyneke F; Maes A; Kratochwil C; Lengana T; Giesel FL; Van de Wiele C; Morgenstern A
    J Nucl Med; 2020 Jan; 61(1):62-69. PubMed ID: 31101746
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.